Increased release of endothelium-derived relaxing factor/nitric oxide has been proposed as the final common pathway for vasodilator responses to gram-negative lipopolysaccharide (endotoxin). To test this hypothesis, we examined endothelium-dependent and endothelium-independent vasodilator agents in vascular smooth muscle isolated from guinea pigs 16 hours after injection of saline (control group) or induction of Escherichia coli endotoxemia; aortic rings ("'1 mm in diameter) were studied with standard isometric tension techniques. Endotoxemia resulted in a significant loss of vasodilator responses to the endothelium-dependent receptor agonists acetylcholine (10-1-105 M) and ADP (10-8-10-M). In contrast, endotoxemia did not affect vasodilator responses to either the endothelium-dependent receptor agonist substance P (10-"-10-7 M), the endothelium-dependent and receptor-independent agonist A23187 (10-9_10-6 M), or the endothelium-independent agonist nitroprusside (1O0-3o10-4 M). The nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) inhibited the vasodilator response to acetylcholine more in vessels from lipopolysaccharide-injected than control guinea pigs. Unexpectedly, L-NAME converted the endothelium-dependent vasodilator action of ADP to an endothelium-dependent vasoconstrictor response that was blocked individually by the cyclooxygenase inhibitor indomethacin, the thromboxane synthase inhibitor dazoxiben, and the thromboxane A2 receptor antagonist SQ29548. We conclude that in vivo endotoxemia inhibits the constitutive isoform of nitric oxide synthase in endothelial cells by selectively disrupting receptor-coupled activation mechanisms shared by acetylcholine and ADP. Furthermore, since L-NAME unmasks a thromboxane A2-mediated vasoconstrictor action of the endogenous purinoceptor agonist ADP, drugs that inhibit nitric oxide synthase could exacerbate sepsis-induced vasoconstriction and ischemia by synergizing with lipopolysaccharide-induced inhibition of endothelial nitric oxide synthase. (Circulation Research 1993;72:539- 
Systemic hypotension associated with the circulatory dysfunction produced by gram-negative lipopolysaccharide (LPS [endotoxin] ) is an important determinant of the morbidity and mortality incurred during the hypodynamic phase of gram-negative sepsis.' Endotoxin-induced changes in blood vessel function are expressed as a heterogeneous pattern of vasodilation and vasoconstriction in different organs, culminating in a fall in total peripheral vascular resistance concomitant with regional maldistribution of 540 Circulation Research Vol 72, No 3 March 1993 The proposal that LPS and its mediators promote the release of EDRF/NO in intact subjects seems inconsistent with some other data suggesting just the opposite in isolated tissues; i.e., LPS and tumor necrosis factor-a seem to interfere with the release of EDRF/NO in different vascular and endothelial preparations. [16] [17] [18] [19] [20] Disparate interpretations about interactions between endotoxin and EDRF/NO based on in vivo versus in vitro experiments partially reflect inherent complexities associated with the study of intact subjects and their multifaceted circulatory responses to LPS and its many endogenous vasoactive mediators. Another confounding influence is that there are different isoforms of NOS, and LPS can modulate NO synthesis in tissues other than blood vessels. 21 Resolution of this complex problem is important because drugs that inhibit NOS have been proposed as novel therapeutic strategies for treating septic shock,'0,'4,'5 and these drugs are now entering clinical trials in patients critically ill with sepsis.1422 In the present study, we focused on LPS-endothelium interrelations; blood vessels were isolated from guinea pigs subjected to a standardized model of Escherichia coli endotoxemia, and endothelium-dependent and endothelium-independent vasoactive agents were compared in an ex vivo environment free from the metabolic and circulatory complexities operative in the intact host.
Materials and Methods
Methods used for inducing endotoxemia in vivo in guinea pigs were reported previously,23-25 as were in vitro techniques for assessing intrinsic contraction-relaxation properties of isolated blood vessels'6; these procedures are summarized below.
Endotoxemia Model
Hartley-strain male albino guinea pigs, weighing between 250 and 400 g, were used throughout the study. Animal room temperature was maintained between 220 and 24°C; a 12-hour light-dark cycle was maintained by artificial illumination; and experiments were timed so that blood vessel isolation began between 8:30 and 9:00 AM. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Missouri, Columbia. Gram-negative endotoxemia was produced by intraperitoneal injection of 4 mg/kg purified E. coli endotoxin (lipopolysaccharide W, 0127:1B8, Difco Laboratories, Detroit, Mich.). Hemodynamic instrumentation was not done in this study; however, we have shown previously that this procedure consistently results in a state of circulatory shock characterized by central nervous system depression, hypothermia, '20% mortality, early compensatory hyperpnea, minimal changes in arterial blood gases, and marked decreases in systolic and diastolic blood pressures by 16-18 hours after injection of endotoxin. 23, 24 In the present study, blood vessels were isolated [16] [17] [18] hours after the injection of either endotoxin or an equivalent volume of sterile isotonic saline solution (control vessels). A control and endotoxemic guinea pig (and respective vessel preparations) were usually examined concurrently to pair environmental influences and nonspecific variables as much All dimensions of aortic and coronary rings isolated for evaluation were similar between control and respective LPS groups (p>0.05).
Aortic vessels were progressively stretched by calculated percentages of the initial resting outer diameter, and contractile responses to 30 mM KCl were determined at each level of stretch until maximal active contractile responses to KCl were obtained. Vessel stretch was recorded as the absolute internal circumferential length at L,,,. Length-dependent active tension responses were essentially identical in control and LPS aortas (p>0.05). Likewise, L,: and resting tension at L.,, in the LPS group were equivalent to corresponding values for control aorta (Table 1) . Neither L-NAME (100 or 300 ,uM) nor L-arginine (1 or 3 mM) affected passive (resting) tension in either LPS (n=8) or control (n=9) aortas (data not shown).
Analogous to findings in aortic rings, values for circumferential length at 180 in coronary arteries were not significantly different in LPS and control groups.
Resting tension at Lo was somewhat lower in coronaries isolated from the LPS animals ( Table 1 ). All subsequent drug response experiments were conducted at optimal resting length for individual coronary and aortic vessels.
Vasoconstrictor Agonists Aortic rings isolated from LPS-injected guinea pigs exhibited =40% reduction in the maximal vasoconstrictor responses to NE; the maximal contractile tension and corresponding EC50 values for NE are summarized in Table 2 for control and LPS aortas. In coronary arterial rings from LPS-injected guinea pigs, vasoconsolutions to the microvessel perfusate. strictor responses to PGF2a were reduced ( Table 2 ). In contrast to the LPS-induced inhibition of responses to the receptor-dependent agonists NE and PGF2a, the maximal and EC50 values for the vasoconstrictor response to K' depolarization were not inhibited in either aortas or coronary vessels of the LPS group (Table 2) . In fact, the maximal K' response was somewhat greater in the LPS group of coronary arteries ( Table 2 ).
Vasodilator Agonists
General. Because of the LPS-induced inhibition of vasoconstrictor responses to receptor-dependent agonists (Table 2) , it was necessary to use either K' (not inhibited by LPS) or different agonist concentrations to achieve equivalent absolute levels of vasoconstrictor tone in control and LPS vessels. NE concentrations near 3 x 10-7 and 10`M were used in control and LPS vessels, respectively, to gain equivalent vasoconstrictor tone of 2-3 g in both groups of aortic rings. This level of NE precontraction was equivalent to the contractions produced by EC50 of K' in both groups. Since NE produces little or no vasoconstriction in guinea pig 100-300-,um coronary arteries (authors' unpublished observations), these vessels were precontracted with either PGFm (from 10`to 3x10-5 M) or K' (30 mM) .
After vasoconstrictor responses to NE, K', or PGF2a achieved equivalent stabilized precontractions, vasodilator responses were determined.
Concentration-dependent vasodilation consistently
was produced by ACh, ADP, substance P, and the Ca2' ionophore A23187; data from control and LPS aortas are contrasted in Figure 1 . Denuding of endothelium inhibited vasodilator responses to ACh, ADP, substance P, and A23187 by 70-95% in both groups of vessels.
Acetylcholine. The vasodilator response to ACh was consistently reduced in aortas from the endotoxin group ( Figure 1A ). Excess L-arginine (1 mM) failed to affect vasodilator responses to ACh alone in either control or LPS populations (Figure 2 ). However, L-NAME (100 or 300 ,uM) consistently inhibited vasodilator responses to ACh in LPS and control vessels, substantially reducing the maximal ACh response by 80-90% ( To determine if reduced vasodilator responses in LPS vessels were restricted to NE-induced precontractions, additional experiments were conducted with control (Figure 4 ). ADP. The vasodilator response to ADP was significantly inhibited in aortas from the endotoxin group ( Figure 1B) . As with the ACh response (Figure 2) , incubation with 1.0 mM L-arginine did not reverse the LPS-induced inhibition of the vasodilator response to ADP ( Figure 5 ).
Preincubation with either dazoxiben or INDO potentiated the vasodilator response to ADP in control and LPS vessels (Figure 6 ), suggesting that ADP exerted a cyclooxygenase and thromboxane synthase-dependent vasoconstrictor action that was masked by simultaneous release of NO. Indeed, L-NAME not only inhibited the endothelium-dependent vasodilator response to ADP but also converted it to an endothelium-dependent vasoconstrictor response in both control and LPS vessels, as shown in Figure 7 . The vasoconstrictor response to ADP expressed in L-NAME-treated vessels was inhibited in both control and LPS groups by 5 ,uM INDO ( Figures 7B and 7F) , by 10 ,uM dazoxiben ( Figures 7C and 7G) , and by 10 gM SQ29548 ( Figures   7D and 7H) .
Substance P. In contrast to LPS-induced inhibition of vasodilator responses to ACh and ADP ( Figures 1A and  1B) , LPS did not affect vasodilator effects of substance P ( Figure 1C ). To ensure that the endothelium-dependent action of substance P was due to NO and not a cyclooxygenase-derived prostanoid, additional experiments were done with L-NAME (300 gM) and INDO (5 ,uM) . INDO Nitroprusside. Nitroprusside produced concentrationdependent vasodilator actions that were virtually identical in control and LPS vessels (Figure 8 ). The vasodilator response to nitroprusside (10-5 M) was similar in endothelium-intact (101+6% relaxation, n = 10) and endothelium-denuded (106+±8% relaxation, n=11) vessels. Similarly, neither INDO nor L-NAME affected the vasodilator effects of nitroprusside in either LPS or control vessels (Figure 8 
LPS and Endothelium-Independent Relaxation of VSM
The vasorelaxant response to nitroprusside was not influenced by removal of endothelium, by L-NAME, or by INDO. These findings confirm that nitroprusside is a directly acting vasodilator that does not require endothelium-derived factors, NOS, or cyclooxygenase products of arachidonic acid. Rather, nitroprusside undergoes tissue-catalyzed reduction yielding NO40; the latter directly activates the cytosolic fraction of VSM guanylyl cyclase with subsequent intracellular increases in the endogenous vasodilator cGMP.7,41 Previous studies have indicated that although LPS can affect cGMP concentrations in VSM under some conditions,33 LPS nevertheless spares the ability of VSM to respond to endothelium-independent vasodilator agents that act through the guanylyl cyclase-cGMP pathway. '6-19 In the present study, endotoxemia affected neither the potency (IC50) nor the efficacy (maximal response) of nitroprusside, resulting in concentration-dependent vasodilator curves in endotoxemic vessels indistinguishable from control curves. We interpret the nitroprusside data as evidence that this LPS model failed to affect either the ability of NO to activate guanylyl cyclase-cGMP33 or the sensitivity of the VSM contractile apparatus34 to cGMP-mediated actions.
LPS and Endothelium-Dependent Relaxation of VSM
In contrast to the direct VSM relaxant action of nitroprusside,40 the vasodilator mechanism for ACh requires a muscarinic receptor-dependent release of endothelium-derived NO synthesized from an NGguanidino nitrogen of L-arginine through the action of NOS.6-8 ADP also activates endothelial NOS through the P2,, subclass of purinergic receptors.2931 Endothelium-derived NO migrates rapidly to nearby VSM, where it confers activation to the catalytic component of guanylyl cyclase, accelerating conversion of GTP to cGMP with subsequent activation of the cGMP-dependent vasorelaxant mechanism.6-8 Since LPS consistently inhibited vasodilator responses to ADP and ACh but did not alter vasorelaxant effects of the directly acting cGMP-dependent nitroprusside, present data are consistent with the interpretation that endotoxemia inhibited the synthesis of endothelium-derived NO rather than affecting NO-guanylyl cyclase interactions or sub- leased by degranulating platelets, and it can further provoke thrombogenesis by autocrine activation of the platelets.29-31 However, ADP can paradoxically antagonize thrombogenesis through its separate endotheliumdependent release of NO. NO is not only a vasodilator; it also is an antiaggregating compound owing to its ability to activate guanylyl cyclase-cGMP within the platelet.51'52 Inhibition of NOS would not only convert ADP-induced vasodilation to thromboxane A2-dependent vasoconstriction, as we now report in a guinea pig aorta model; it might also exacerbate thrombogenesis through an inhibition of the antiplatelet action of NO concomitant with unmasking platelet-aggregating actions of the nascent thromboxane A2.31 Theoretically, therefore, NOS inhibition during sepsis could provoke arterial vasospasm and tissue ischemia while concomitantly inducing platelet aggregation, leading perhaps to disseminated intravascular coagulation. These possibilities caution that NOS inhibitors should not be used clinically until further studies in animals better define the pharmacodynamic profile and potential toxic side effects of these complex agents.
